<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='199'><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="799">Ovary tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2003-10-13 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="49">Breast tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2000-10-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26231">FGene SA</Company><Country id="FR">France</Country><Drug id="21923">FG-003</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-02-06 00:00:00</LatestChange><ParentCompany id="26231">FGene SA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-02-06 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="CZ">Czech Republic</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1999-03-05 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="PL">Poland</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1999-01-11 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="HU">Hungary</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1998-12-04 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="CA">Canada</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1996-02-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1070404">CARLINA Technologies SAS</Company><Country id="FR">France</Country><Drug id="81585">PEPTIDOTS-IL2 (sustained release/sc, kidney/skin cancer), CARLINA Technologies</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-10-25 00:00:00</LatestChange><ParentCompany id="1070404">CARLINA Technologies SAS</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-10-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="318">Systemic lupus erythematosus</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2204">Ascites</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26794">CytImmune Sciences Inc</Company><Country id="US">US</Country><Drug id="55676">CYT-51000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-22 00:00:00</LatestChange><ParentCompany id="26794">CytImmune Sciences Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2006-02-06 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="746">Infectious disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17255">Introgen Therapeutics Inc</Company><Country id="US">US</Country><Drug id="14960">INGN-301</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="17255">Introgen Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-11-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17255">Introgen Therapeutics Inc</Company><Country id="US">US</Country><Drug id="14960">INGN-301</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="17255">Introgen Therapeutics Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-11-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2001-11-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003462">Cell-Medicine Inc</Company><Country id="JP">Japan</Country><Drug id="55115">AFTVac</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-16 00:00:00</LatestChange><ParentCompany id="1003462">Cell-Medicine Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1148">Sjoegrens syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2204">Ascites</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="746">Infectious disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1261">Small-cell lung cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-10-24 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="989">Colorectal tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2003-10-13 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007204">Altor BioScience Corp</Company><Country id="US">US</Country><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-31 00:00:00</LatestChange><ParentCompany id="1007204">Altor BioScience Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2007-07-10 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000087">Orient Europharma</Company><Country id="TW">Taiwan</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="DOL1000087">Orient Europharma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2000-11-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021861">Ergomed Group</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="427">Uterine cervix tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="1021861">Ergomed Group</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2013-10-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="1521">Gynecology and obstetrics</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="1232">Condyloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-04-21 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1016672">3SBio Inc</Company><Country id="CN">China</Country><Drug id="79719">interleukin-2, 3SBio</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3546">Pulmonary edema</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1084373">Decade Sunshine Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1996-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072303">Laboratorios Bioprofarma</Company><Country id="AR">Argentina</Country><Drug id="80440">interleukin-2 follow-on biologic, Laboratorios Bioprofarma</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3467">Metastatic renal cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-22 00:00:00</LatestChange><ParentCompany id="14346">Bago</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-08-22 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2204">Ascites</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29496">The Center of Molecular Immunology</Company><Country id="CU">Cuba</Country><Drug id="83496">IL-2 variant mutant (cancer), The Center of Molecular Immunology</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-02-22 00:00:00</LatestChange><ParentCompany id="29496">The Center of Molecular Immunology</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-02-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><Drug id="84550">glucocorticoid/rIL-2 (inflammation/immune-mediated disorders/transplant rejection), NCI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="515">Transplant rejection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-08-31 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="84550">glucocorticoid/rIL-2 (inflammation/immune-mediated disorders/transplant rejection), NCI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="515">Transplant rejection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-08-31 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="318">Systemic lupus erythematosus</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-01-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21864">University of Texas System</Company><Country id="US">US</Country><Drug id="14960">INGN-301</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="21864">University of Texas System</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003462">Cell-Medicine Inc</Company><Country id="JP">Japan</Country><Drug id="55115">AFTVac</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-16 00:00:00</LatestChange><ParentCompany id="1003462">Cell-Medicine Inc</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2006-03-31 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1148">Sjoegrens syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="755">Lung tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="25767">Seragen Inc</Company><Country id="FR">France</Country><Drug id="12802">DAB-486-IL-2</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="836">Insulin dependent diabetes</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-07-23 12:14:39</LatestChange><ParentCompany id="17808">Ligand Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1996-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25767">Seragen Inc</Company><Country id="US">US</Country><Drug id="12802">DAB-486-IL-2</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-07-23 12:14:39</LatestChange><ParentCompany id="17808">Ligand Pharmaceuticals Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1996-07-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1261">Small-cell lung cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2007-10-24 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="760">Brain tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2000-10-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1262">Non-small-cell lung cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-04-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007204">Altor BioScience Corp</Company><Country id="US">US</Country><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3466">Metastatic bladder cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-31 00:00:00</LatestChange><ParentCompany id="1007204">Altor BioScience Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-06-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007204">Altor BioScience Corp</Company><Country id="US">US</Country><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-31 00:00:00</LatestChange><ParentCompany id="1007204">Altor BioScience Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2012-08-31 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1017656">Botanic Oil Innovations Inc</Company><Country id="US">US</Country><Drug id="70160">salmonella-IL-2 cancer therapy (oral, cancer), Botanic Oil Innovations</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-17 00:00:00</LatestChange><ParentCompany id="1017656">Botanic Oil Innovations Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-10-17 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="DOL1000087">Orient Europharma</Company><Country id="TW">Taiwan</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="DOL1000087">Orient Europharma</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-05-18 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="TR">Turkey</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="20348">Teva Pharmaceutical Industries Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="IL">Israel</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="20348">Teva Pharmaceutical Industries Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-08-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="1232">Condyloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-10-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="29050">NanoCarrier Co Ltd</Company><Country id="US">US</Country><Drug id="83107">IL-2 micelle (renal cancer, nanoparticle), Nanocarrier</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-09-20 00:00:00</LatestChange><ParentCompany id="29050">NanoCarrier Co Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-09-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007327">Yokohama City University</Company><Country id="JP">Japan</Country><Drug id="84680">oligodeoxynucleotides expressing poly-G motif (cancer), Yokohama City University/National Cancer Institute/Tohoku University</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-10-31 00:00:00</LatestChange><ParentCompany id="1007327">Yokohama City University</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-10-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-01-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="203">Lymphoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17255">Introgen Therapeutics Inc</Company><Country id="US">US</Country><Drug id="14960">INGN-301</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="17255">Introgen Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-04-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2000-10-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="276">Prostate tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-08-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="1785">Andrology</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007204">Altor BioScience Corp</Company><Country id="US">US</Country><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3257">Stage IV melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-31 00:00:00</LatestChange><ParentCompany id="1007204">Altor BioScience Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-02-28 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1016672">3SBio Inc</Company><Country id="CN">China</Country><Drug id="79719">interleukin-2, 3SBio</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1084373">Decade Sunshine Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1016672">3SBio Inc</Company><Country id="CN">China</Country><Drug id="79719">interleukin-2, 3SBio</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1084373">Decade Sunshine Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1996-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071442">Amega Biotech</Company><Country id="AR">Argentina</Country><Drug id="79856">IL-2 follow-on biologic, Amega</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-30 00:00:00</LatestChange><ParentCompany id="1071442">Amega Biotech</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-07-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="DOL1000087">Orient Europharma</Company><Country id="IN">India</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="DOL1000087">Orient Europharma</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-05-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021861">Ergomed Group</Company><Country id="DE">Germany</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="1021861">Ergomed Group</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2013-04-24 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="RS">Serbia</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="20348">Teva Pharmaceutical Industries Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-07-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="BY">Belarus</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-02-27 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1028796">Amoytop Biotech Co Ltd</Company><Country id="CN">China</Country><Drug id="81551">interleukin-2 follow-on biologic, Amoytop</Drug><EntityType>Biological</EntityType><HighestDevStatus id="CU">Clinical</HighestDevStatus><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="3257">Stage IV melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-10-16 00:00:00</LatestChange><ParentCompany id="1028796">Amoytop Biotech Co Ltd</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2012-10-16 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1028796">Amoytop Biotech Co Ltd</Company><Country id="CN">China</Country><Drug id="81551">interleukin-2 follow-on biologic, Amoytop</Drug><EntityType>Biological</EntityType><HighestDevStatus id="CU">Clinical</HighestDevStatus><HighestDevStatusForInd id="CU">Clinical</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-10-16 00:00:00</LatestChange><ParentCompany id="1028796">Amoytop Biotech Co Ltd</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2012-10-16 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="IL">Israel</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>1997-04-01 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="IL">Israel</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="49">Breast tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1029201">Shanghai Hua Xin High Biotechnology Inc</Company><Country id="CN">China</Country><Drug id="79382">recombinant human interleukin-2 (freeze-dried), Shanghai Hua Xin High Biotechnology Inc</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1029201">Shanghai Hua Xin High Biotechnology Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1029201">Shanghai Hua Xin High Biotechnology Inc</Company><Country id="CN">China</Country><Drug id="79382">recombinant human interleukin-2 (freeze-dried), Shanghai Hua Xin High Biotechnology Inc</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1029201">Shanghai Hua Xin High Biotechnology Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><Drug id="86441">RDB-1450</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="185">Immune disorder</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-13 00:00:00</LatestChange><ParentCompany id="14005">Alkermes plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-04-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071264">American Biosources Inc</Company><Country id="US">US</Country><Drug id="86543">interleukin 2 biosimilar API, American Biosources</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1005">Unidentified indication</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-07-23 00:00:00</LatestChange><ParentCompany id="1071264">American Biosources Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-07-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="1005">Unidentified indication</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1083848">BioGeneric Pharma</Company><Country id="EG">Egypt</Country><Drug id="85661">human interleukin-2 follow-on biologic, BioGeneric Pharma</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2013-05-21 00:00:00</LatestChange><ParentCompany id="1083848">BioGeneric Pharma</ParentCompany><Status id="L">Launched</Status><StatusDate>2013-05-21 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="746">Infectious disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="203">Lymphoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21864">University of Texas System</Company><Country id="US">US</Country><Drug id="14960">INGN-301</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="21864">University of Texas System</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-10-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-03-15 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="203">Lymphoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2204">Ascites</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="318">Systemic lupus erythematosus</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003462">Cell-Medicine Inc</Company><Country id="JP">Japan</Country><Drug id="55115">AFTVac</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1767">Hepatocellular carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-16 00:00:00</LatestChange><ParentCompany id="1003462">Cell-Medicine Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15489">Weizmann Institute of Science</Company><Country id="IL">Israel</Country><Drug id="7267">interleukin-2-like growth factor, Yeda</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="233">Neurodegenerative disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-03-16 00:00:00</LatestChange><ParentCompany id="15489">Weizmann Institute of Science</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="203">Lymphoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="203">Lymphoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="746">Infectious disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="989">Colorectal tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2005-04-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007204">Altor BioScience Corp</Company><Country id="US">US</Country><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-31 00:00:00</LatestChange><ParentCompany id="1007204">Altor BioScience Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-12-20 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="276">Prostate tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="1785">Andrology</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="1517">Anal dysplasia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-10-07 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1064383">IDC-GP Pharm LLC</Company><Country id="AR">Argentina</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="1064383">IDC-GP Pharm LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-08-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="MY">Malaysia</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-02-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2010-12-22 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="CA">Canada</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-05-17 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="IL">Israel</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1998-11-03 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1016672">3SBio Inc</Company><Country id="CN">China</Country><Drug id="79719">interleukin-2, 3SBio</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1084373">Decade Sunshine Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>1996-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1029201">Shanghai Hua Xin High Biotechnology Inc</Company><Country id="CN">China</Country><Drug id="79382">recombinant human interleukin-2 (freeze-dried), Shanghai Hua Xin High Biotechnology Inc</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1029201">Shanghai Hua Xin High Biotechnology Inc</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1021416">Zenotech Laboratories Ltd</Company><Country id="IN">India</Country><Drug id="79967">interleukin-2 follow-on-biologic, Zenotech</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-03-31 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2005-03-31 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="755">Lung tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="318">Systemic lupus erythematosus</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14005">Alkermes plc</Company><Country id="US">US</Country><Drug id="86441">RDB-1450</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-04-13 00:00:00</LatestChange><ParentCompany id="14005">Alkermes plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-07-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1148">Sjoegrens syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1045268">Provecs Medical GmbH</Company><Country id="DE">Germany</Country><Drug id="62423">immunostimulant (cancer/infection/vaccination), Provecs</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="746">Infectious disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-11-01 00:00:00</LatestChange><ParentCompany id="1045268">Provecs Medical GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-11-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2003-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30593">AplaGen GmbH</Company><Country id="DE">Germany</Country><Drug id="53507">IL-2 mimetic peptides (cancer immunotherapy), AplaGen</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-27 00:00:00</LatestChange><ParentCompany id="30593">AplaGen GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2005-05-13 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="30593">AplaGen GmbH</Company><Country id="DE">Germany</Country><Drug id="53507">IL-2 mimetic peptides (cancer immunotherapy), AplaGen</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2011-12-27 00:00:00</LatestChange><ParentCompany id="30593">AplaGen GmbH</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2011-12-27 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="318">Systemic lupus erythematosus</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25767">Seragen Inc</Company><Country id="US">US</Country><Drug id="12802">DAB-486-IL-2</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="230">Neoplasm</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-07-23 12:14:39</LatestChange><ParentCompany id="17808">Ligand Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1996-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25767">Seragen Inc</Company><Country id="US">US</Country><Drug id="12802">DAB-486-IL-2</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-07-23 12:14:39</LatestChange><ParentCompany id="17808">Ligand Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1996-07-23 12:14:39</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="799">Ovary tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2007-10-24 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26231">FGene SA</Company><Country id="FR">France</Country><Drug id="21923">FG-003</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-02-06 00:00:00</LatestChange><ParentCompany id="26231">FGene SA</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1999-02-04 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="760">Brain tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2002-02-15 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><Drug id="57922">NHS-IL2-LT</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-22 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="X5">Europe</Country><Drug id="57922">NHS-IL2-LT</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-22 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2006-12-31 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007204">Altor BioScience Corp</Company><Country id="US">US</Country><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-31 00:00:00</LatestChange><ParentCompany id="1007204">Altor BioScience Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2003-11-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007204">Altor BioScience Corp</Company><Country id="US">US</Country><Drug id="63685">ALT-801 (donor lymphocyte infusion, cancer), Altor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-11 00:00:00</LatestChange><ParentCompany id="1007204">Altor BioScience Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2011-06-29 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="X5">Europe</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-05-13 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="IL">Israel</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="49">Breast tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="CU">Clinical</Status><StatusDate>2000-05-24 00:00:00</StatusDate><StatusSortCode>7</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="427">Uterine cervix tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2001-05-08 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="1521">Gynecology and obstetrics</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="276">Prostate tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>1998-11-03 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="1785">Andrology</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2008-10-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1148">Sjoegrens syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1072303">Laboratorios Bioprofarma</Company><Country id="AR">Argentina</Country><Drug id="80440">interleukin-2 follow-on biologic, Laboratorios Bioprofarma</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-08-22 00:00:00</LatestChange><ParentCompany id="14346">Bago</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-08-22 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="84550">glucocorticoid/rIL-2 (inflammation/immune-mediated disorders/transplant rejection), NCI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="185">Immune disorder</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-08-31 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2003-04-30 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2002-06-05 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1045268">Provecs Medical GmbH</Company><Country id="DE">Germany</Country><Drug id="62423">immunostimulant (cancer/infection/vaccination), Provecs</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-11-01 00:00:00</LatestChange><ParentCompany id="1045268">Provecs Medical GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-11-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="755">Lung tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="18924">Farmitalia Carlo Erba Srl</Company><Country id="IT">Italy</Country><Drug id="7267">interleukin-2-like growth factor, Yeda</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="233">Neurodegenerative disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-03-16 00:00:00</LatestChange><ParentCompany id="18767">Pfizer Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21864">University of Texas System</Company><Country id="US">US</Country><Drug id="14960">INGN-301</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="21864">University of Texas System</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-11-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15489">Weizmann Institute of Science</Company><Country id="IT">Italy</Country><Drug id="7267">interleukin-2-like growth factor, Yeda</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="233">Neurodegenerative disease</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-03-16 00:00:00</LatestChange><ParentCompany id="15489">Weizmann Institute of Science</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-03-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="677">Neurological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2204">Ascites</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="755">Lung tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003462">Cell-Medicine Inc</Company><Country id="JP">Japan</Country><Drug id="55115">AFTVac</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="2454">Glioblastoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-16 00:00:00</LatestChange><ParentCompany id="1003462">Cell-Medicine Inc</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2010-06-06 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1003462">Cell-Medicine Inc</Company><Country id="JP">Japan</Country><Drug id="55115">AFTVac</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-03-16 00:00:00</LatestChange><ParentCompany id="1003462">Cell-Medicine Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2002-04-30 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="799">Ovary tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>2008-04-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="49">Breast tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="112">Endocrine disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="276">Prostate tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="1785">Andrology</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="19862">Merck Serono SA</Company><Country id="US">US</Country><Drug id="57922">NHS-IL2-LT</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C2">Phase 2 Clinical</HighestDevStatus><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-22 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2014-01-22 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1029201">Shanghai Hua Xin High Biotechnology Inc</Company><Country id="CN">China</Country><Drug id="79382">recombinant human interleukin-2 (freeze-dried), Shanghai Hua Xin High Biotechnology Inc</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1029201">Shanghai Hua Xin High Biotechnology Inc</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1064383">IDC-GP Pharm LLC</Company><Country id="VE">Venezuela</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="1064383">IDC-GP Pharm LLC</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-08-23 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="PH">Philippines</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2015-02-11 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>1996-02-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1016672">3SBio Inc</Company><Country id="CN">China</Country><Drug id="79719">interleukin-2, 3SBio</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1084373">Decade Sunshine Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><Drug id="84550">glucocorticoid/rIL-2 (inflammation/immune-mediated disorders/transplant rejection), NCI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="188">Inflammatory disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-08-31 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><Drug id="84550">glucocorticoid/rIL-2 (inflammation/immune-mediated disorders/transplant rejection), NCI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="185">Immune disorder</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-08-31 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><Drug id="84550">glucocorticoid/rIL-2 (inflammation/immune-mediated disorders/transplant rejection), NCI</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="188">Inflammatory disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2004-08-31 00:00:00</LatestChange><ParentCompany id="20516">US Government</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2004-08-31 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="188">Inflammatory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="1021416">Zenotech Laboratories Ltd</Company><Country id="IN">India</Country><Drug id="79967">interleukin-2 follow-on-biologic, Zenotech</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2008-03-31 00:00:00</LatestChange><ParentCompany id="1017506">Daiichi Sankyo Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2008-03-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="755">Lung tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="203">Lymphoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="26794">CytImmune Sciences Inc</Company><Country id="US">US</Country><Drug id="55676">CYT-51000</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="725">Solid tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-22 00:00:00</LatestChange><ParentCompany id="26794">CytImmune Sciences Inc</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-22 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1045268">Provecs Medical GmbH</Company><Country id="DE">Germany</Country><Drug id="62423">immunostimulant (cancer/infection/vaccination), Provecs</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="202">Liver tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-11-01 00:00:00</LatestChange><ParentCompany id="1045268">Provecs Medical GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-11-01 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1148">Sjoegrens syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2204">Ascites</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="755">Lung tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="17255">Introgen Therapeutics Inc</Company><Country id="US">US</Country><Drug id="14960">INGN-301</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="17255">Introgen Therapeutics Inc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>1997-10-08 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2009-01-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-06-05 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21864">University of Texas System</Company><Country id="US">US</Country><Drug id="14960">INGN-301</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2001-11-28 00:00:00</LatestChange><ParentCompany id="21864">University of Texas System</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2001-11-28 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1046040">Byron Biopharma</Company><Country id="ZA">South Africa</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="1046040">Byron Biopharma</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2009-03-09 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1021861">Ergomed Group</Company><Country id="DE">Germany</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="1232">Condyloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="1021861">Ergomed Group</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-02-11 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="IL">Israel</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="20348">Teva Pharmaceutical Industries Ltd</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2012-05-18 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="HR">Croatia</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="20348">Teva Pharmaceutical Industries Ltd</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2011-07-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="BA">Bosnia and Herzegovina</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-12-05 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="LK">Sri Lanka</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-07-17 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="X2">Asia</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C3">Phase 3 Clinical</Status><StatusDate>2011-12-07 00:00:00</StatusDate><StatusSortCode>10</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="TR">Turkey</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="623">Head and neck tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-07-22 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="2193">Anal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2012-11-14 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="129">Gastrointestinal disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="15339">CEL-SCI Corp</Company><Country id="US">US</Country><Drug id="7401">Multikine</Drug><EntityType>Biological</EntityType><HighestDevStatus id="C3">Phase 3 Clinical</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2015-02-27 00:00:00</LatestChange><ParentCompany id="15339">CEL-SCI Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>1997-01-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="25767">Seragen Inc</Company><Country id="US">US</Country><Drug id="12802">DAB-486-IL-2</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="158">HIV infection</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>1996-07-23 12:14:39</LatestChange><ParentCompany id="17808">Ligand Pharmaceuticals Inc</ParentCompany><Status id="DX">Discontinued</Status><StatusDate>1996-07-23 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2003-10-13 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="21956">EMD Lexigen Research Center Corp</Company><Country id="US">US</Country><Drug id="21065">tucotuzumab celmoleukin</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DX">Discontinued</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1262">Non-small-cell lung cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2008-04-23 00:00:00</LatestChange><ParentCompany id="18101">Merck KGaA</ParentCompany><Status id="C2">Phase 2 Clinical</Status><StatusDate>2000-10-27 00:00:00</StatusDate><StatusSortCode>9</StatusSortCode><TherapyArea id="711">Respiratory disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1007204">Altor BioScience Corp</Company><Country id="US">US</Country><Drug id="63685">ALT-801 (donor lymphocyte infusion, cancer), Altor</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-09-11 00:00:00</LatestChange><ParentCompany id="1007204">Altor BioScience Corp</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-09-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1070404">CARLINA Technologies SAS</Company><Country id="FR">France</Country><Drug id="81585">PEPTIDOTS-IL2 (sustained release/sc, kidney/skin cancer), CARLINA Technologies</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="2170">Skin cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-10-25 00:00:00</LatestChange><ParentCompany id="1070404">CARLINA Technologies SAS</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-10-25 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="999">Renal tumor</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="746">Infectious disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1077532">Shandong Quangang Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><Drug id="82874">interleukin-2 follow-on biologic, Shandong Quangang Pharmaceutical</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1148">Sjoegrens syndrome</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2001-12-31 00:00:00</LatestChange><ParentCompany id="1077532">Shandong Quangang Pharmaceutical Co Ltd</ParentCompany><Status id="L">Launched</Status><StatusDate>2001-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1071442">Amega Biotech</Company><Country id="AR">Argentina</Country><Drug id="79856">IL-2 follow-on biologic, Amega</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="205">Melanoma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2012-07-30 00:00:00</LatestChange><ParentCompany id="1071442">Amega Biotech</ParentCompany><Status id="L">Launched</Status><StatusDate>2012-07-30 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1017656">Botanic Oil Innovations Inc</Company><Country id="US">US</Country><Drug id="70160">salmonella-IL-2 cancer therapy (oral, cancer), Botanic Oil Innovations</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-10-17 00:00:00</LatestChange><ParentCompany id="1017656">Botanic Oil Innovations Inc</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2010-04-06 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1045268">Provecs Medical GmbH</Company><Country id="DE">Germany</Country><Drug id="62423">immunostimulant (cancer/infection/vaccination), Provecs</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="384">Vaccination</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2011-11-01 00:00:00</LatestChange><ParentCompany id="1045268">Provecs Medical GmbH</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2008-11-18 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="706">Prophylaxis</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1079335">Guangdong Weilun Biological Products Co Ltd</Company><Country id="CN">China</Country><Drug id="84921">interleukin-2 follow-on biologic, Guangdong Weilun Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="746">Infectious disease</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2005-12-31 00:00:00</LatestChange><ParentCompany id="1079335">Guangdong Weilun Biological Products Co Ltd</ParentCompany><Status id="R">Registered</Status><StatusDate>2005-12-31 00:00:00</StatusDate><StatusSortCode>12</StatusSortCode><TherapyArea id="746">Infectious disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="14455">Bayer AG</Company><Country id="US">US</Country><Drug id="28450">BAY-50-4798</Drug><EntityType>Biological</EntityType><HighestDevStatus id="NDR">No Development Reported</HighestDevStatus><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1766">Renal cell carcinoma</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2009-01-29 00:00:00</LatestChange><ParentCompany id="14455">Bayer AG</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2002-06-05 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="366">Genitourinary disease</TherapyArea></Row><Row><Action id="221">IL-2 agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1010156">Changchun Institute of Biological Products</Company><Country id="CN">China</Country><Drug id="79074">interleukin-2 follow-on biologic, Changchun Institute of Biological Products</Drug><EntityType>Biological</EntityType><HighestDevStatus id="L">Launched</HighestDevStatus><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="318">Systemic lupus erythematosus</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>1997-12-31 00:00:00</LatestChange><ParentCompany id="1055632">Sinopharm</ParentCompany><Status id="L">Launched</Status><StatusDate>1997-12-31 00:00:00</StatusDate><StatusSortCode>13</StatusSortCode><TherapyArea id="95">Dermatological disease</TherapyArea></Row></Rowset>